Tenet Healthcare (Tenet Healthcare) Risk Assessment

View and export this data going back to 1976. Start your Free Trial

What is Tenet Healthcare Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Tenet Healthcare is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Tenet Healthcare's Risk Assessment

For the Medical Care Facilities subindustry, Tenet Healthcare's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenet Healthcare's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Tenet Healthcare's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Tenet Healthcare's Risk Assessment falls into.

Tenet Healthcare (NYSE:THC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Tenet Healthcare Risk Assessment Related Terms

Thank you for viewing the detailed overview of Tenet Healthcare's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenet Healthcare (Tenet Healthcare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Tenet Healthcare Corp (NYSE:THC) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

THC:Mexico THC1:Germany

Address

14201 Dallas Parkway, Dallas, TX, USA, 75254

Website

https://www.tenethealth.com

Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 60 as of June 2023) and over 550 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.

Executives

Richard W Fisher	director
Roy Blunt	director	2702 LOVE FIELD DRIVE, HDQ 4GC, DALLAS TX 75235
Paola M Arbour	officer: EVP, Chief Information Officer	14201 DALLAS PARKWAY, DALLAS TX 75254
Stephen H Rusckowski	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Thomas W Arnst	officer: EVP, Chief Admin. Officer & GC	14201 DALLAS PARKWAY, DALLAS TX 75254
Tammy Romo	director	C/O SOUTHWEST AIRINES CO., 2702 LOVE FIELD DR., DALLAS TX 75235
Daniel J Cancelmi	officer: Principal Accounting Officer	13737 NOEL ROAD, SUITE 100, DALLAS TX 75240
J Robert Kerrey	director	NEW SCHOOL UNIVERSITY, 66 W. 12TH STREET, NEW YORK NY 10036
Richard J Mark	director	1901 CHOUTEAU AVENUE MC-1310, ST. LOUIS MO 63103
Ronald A Rittenmeyer	director	5400 LEGACY DRIVE, PLANO TX 75024
Lisa Y Foo	officer: EVP, Commercial Ops	14201 DALLAS PARKWAY, DALLAS TX 75254
Audrey T. Andrews	officer: SVP and General Counsel	1445 ROSS AVENUE, SUITE 1400, DALLAS TX 75202
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Howard Hacker	officer: EVP, Chief Compliance Officer	14201 DALLAS PARKWAY, DALLAS TX 75254
Marie Quintana	officer: EVP, Marketing/Communications	14201 DALLAS PARKWAY, DALLAS TX 75254